TNFRSF18 and cancer: Other antibodies targeting stimulatory or inhibitory coreceptors, including OX40, LAG-3, CD70, and GITR, are being tested in cancer studies as Afuc forms to enhance antibody immunomodulatory functions in vivo (59).